NonSmallCellLungCancer Archives

Browsing: NonSmallCellLungCancer

FDA Grants Priority Review Zongertinib for HER2-Mutant NSCLC | Breakthrough in Lung Cancer Treatment

A Novel Tyrosine Kinase Inhibitor Poised to Transform Advanced Lung Cancer Care Boehringer Ingelheim | Ridgefield, Conn., and Ingelheim, Germany…

FDA Approves Durvalumab / IMFINZI® for Resectable NSCLC Non-Small Cell Lung Cancer

Lung 3 Mins Read

On August 15, 2024, the U.S. Food and Drug Administration (FDA) approved durvalumab (IMFINZI®, AstraZeneca) in combination with platinum-containing chemotherapy…